#RNL2023 AGATA trial showed benefit of Abatecept in GCA - 48 to 31% disease free survival Robert Spiera @RheumNow https://t.co/pPzbdTTvEi

#RNL2023 Rob Spiera: I often use aspirin a day, especially if cranial complications and no contra-indications" No prospective studies, 2 large retrospective studies suggesting benefit @RheumNow https://t.co/OedVG03yN3

#RNL2023 Resources for pregnancy and lactation for patients on various #medications and #chronic #diseases. Have a look. Pregnant 🫃 #baby and #breast #feeding. https://t.co/A8zmBUAylG

Is there role for MTX in GCA Favorable results in a meta-analysis with NNT 11 to prevent 1 cranial relapse BUT: limitations of meta-analysis, short follow-up, dose response not evaluated Robert Spiera at #RNL2023 @RheumNow https://t.co/sHx2ceVmAi

DMARDs/TNF for PMR: MTX- initial benefit, but no 5 year steroid sparing effect Infliximab - no benefit Lef - some benefit in case series Robert Spiera #RNL2023 @RheumNow https://t.co/cmwGEWHQEO

IL-6 for PMR SPARE and SEMAPORE (Toci), SAPHYR (Sari) 2/2023: FDA approves sarilumab for PMR for inadequate response to corticosteroids or unable to taper off Robert Spiera @RheumNow #RNL2023 https://t.co/quOWjJjgB3

Dr. Robert Spiera on Recent IL-6i in PMR treatment: SPARE and SEMAPHORE study - Tocilizumab SAPHYR - Sarilumab (now FDA approved for PMR tx) @RheumNow #RNL2023 https://t.co/gofe54wSjo

SAPHYR, presented at #ACR22, unpublished Robert Spiera at #RNL2023 Phase 3 study for refractory PMR Sustained remission of disease, less steroids usage, steroid toxicity, and improved PROs @RheumNow https://t.co/k3w2TQ3yEB

@anisha_dua reviews considerations for your differential for PMR at #RNL2023 @RheumNow https://t.co/3ZsczB1UKH

I use US in my practice and since this data was presented last year, I’ve been evaluating subacromial/deltoid bursas my PMR patients. ⁦@anisha_dua⁩ reviews imaging at #RNL2023 ⁦@RheumNow⁩ https://t.co/1TYdXNmcx0